Morning Briefing
Summaries of health policy coverage from major news organizations
Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment
Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
